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ABSTRACT
As more studies accumulate on the impact of diabetes mellitus on the central nervous
system, they resound with the same conclusion - diabetes has a detrimental effect on cognition
regardless of the presence of comorbidities. Less consistent however, are the specific mental
processes wherein these declines are noticeable, and the structural changes that accompany these
reductions in mental capacity. From global atrophy to changes in the volume of gray and white
matter, to conflicting results regarding the effects of hypo- and hyperglycemic states on the
development of the hippocampus, the studies display a variety of results. The goal of this
research is to link the structural and compositional changes occurring in the diabetic brain with
the clinical and behavioral findings highlighted in the literature, as well as to explore the
potential mechanisms behind the pathologic brain state of diabetic encephalopathy.
Using diabetic (OVE26) and non-diabetic wild type (FVB) mice as models, differences in
the number of hippocampal neurons in the dentate gyrus, and cornu ammonis areas 1,2, and 3
were investigated through Nissl staining. Neurodegeneration was confirmed in those cells
determined to be hyperchromatic in the diabetic model through staining with Fluoro-Jade C.
Finally, the presence of progenitor cells in the hippocampus was compared in the diabetic and
non-diabetic models using Musashi-1 antibodies, to determine whether neurogenesis in these
areas is affected by diabetes. These experiments were performed to better understand the effect
of DM on learning and memory, and could potentially explain the linkage between diabetes
mellitus and the increased prevalence of Alzheimer’s disease, vascular dementia, and depression
in this subset of the population.
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INTRODUCTION
Diabetes mellitus is a disease wherein glucose uptake from the bloodstream into cells is
inhibited, leading to retinopathy, nephropathy, vasculopathy, and disturbances of the autonomic
nervous system.1 Moreover, diabetes has been shown to have significant effects on cognition
through neural structural changes; therefore the focus of our study was to determine the effects
of diabetes mellitus on the brain. Evidence suggests that both type I and type II diabetics have an
increased risk of acquiring vascular dementia and Alzheimer’s disease, and a greater chance of
suffering cognitive impairments.2 Cognitive decline is also more likely to occur by 60-100% if
an individual with diabetes has chronic hyperglycemia.3 The decline is characterized by “neural
slowing, attention deficit, and [difficulties in] executive functioning,” and type I diabetics were
shown to have lower verbal and overall IQ scores in bouts of acute hyperglycemia in which
blood glucose concentrations were above 15 mM.3 This may be due to a regulatory mechanism
found in type I diabetic patients, but not in their type II counterparts, in which cerebral blood
flow increased during periods of hypoglycemia and decreased during periods of hyperglycemia.2
Possibly akin to the way in which cerebral blood flow is increased in cases of chronic hypoxia,
or hypercapnia, by affecting capillary density and vasodilating blood vessels, the opposite effect
may be taking place in the brain when blood glucose concentration is too high.4 Moreover,
decreased cerebral blood flow has been linked to total brain volume atrophy in Voxel-based
morphometry studies, and arterial spin labeling MRI studies confirm this by showing evidence of
cortical and subcortical atrophy.3, 5
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In type II diabetics, on the other hand, hippocampal atrophy associated with memory
impairment is more prominent, which may be due to the fact that the onset of type II diabetes
often occurs in older patients.3 Since type II diabetes is caused by insulin insensitivity,
hippocampal atrophy may be explained by the fact that insulin prevents the binding of
pathogenic Aβ oligomers to “sites localized at hippocampal nerve cell synapses,” and if proper
insulin binding cannot occur, this CNS protection is no longer present.5 Extended episodes of
severe hypoglycemia are also known to cause the direct necrosis of these neurons.3 Of the areas
most severely affected, the limbic unci and cerebellar posterior lobe, structures associated with
language, affect, and executive function, are linked to the greatest loss of gray matter density.3
Voxel-based morphometry also revealed some of the more subtle structural changes that occur at
the earlier stages of type II diabetes, which included “global brain volume atrophy, hippocampal
and amygdala atrophy, and gray and white matter atrophy in the right temporal lobe.”5 The
subsequent cognitive dysfunction and dementia that was observed in tandem was accounted to
cerebral hypoperfusion, since perfusion is one of the main indicators utilized in measuring tissue
function.5 While this decrease in perfusion was observed in type II patients, in rodent studies
involving Streptozotocin-injected animals, which simulate the type I diabetic model via toxic
destruction of pancreatic β-cells, the number of BBB tight junction proteins decreased, thereby
increasing the permeability and perfusion of the blood brain barrier.2, 6 On the whole, the
structural and neurophysiological modifications that have been found in the brains of type I and
type II diabetic patients are significant enough to be considered a diabetic encephalopathy
because of the cognitive deficits incurred as a result.7 The overall progression of the disease has
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been succinctly summarized as “accelerated brain aging,” and both hypoglycemic and
hyperglycemic episodes have been the suspected causes in varying studies.5, 8
The purpose of this research was to determine whether signs of neurodegeneration, as
well as disturbed neurogenesis were present in diabetic versus wild type mice, as a model of
potential findings for this disease state in humans. According to one study wherein hippocampal
neurogenesis was impaired via irradiation, the mice later showed deficits in retention of spatial
memory, and overall reduced cognition.9 Even age-related reductions in the ability to generate
new neurons in the hippocampus have been implicated as the source of impaired learning.10
Therefore, we carried out a series of experiments using frozen leftover brain tissues from OVE26
(diabetic) and FVB (wild type) mice from Dr. Cheng’s prior experiments, to see whether these
patterns of increased neurodegeneration and decreased neurogenesis were present.
The OVE26 mice that were used in these experiments are transgenic variants of the FVB
mice, and portray an early type I diabetic model.11 The insulin calmodulin gene in these mice is
overexpressed, resulting in β cell toxicity that is sufficient enough to induce type I diabetes, but
allows a small proportion of cells to survive so that the mouse can live for at least a year without
insulin treatment.11 In addition to type I diabetes, these mice typically display characteristics
such as decreased glomerular filtration rate, hypoalbuminemia, and high blood pressure as
complications of their underlying condition.11
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MATERIALS AND METHODS
The specific aims of this research were as follows: 1) to determine changes in
neurodegeneration between diabetic and nondiabetic mice in the dentate gyrus, CA1, CA2, and
CA3 regions of the hippocampus by means of histological analysis, and 2) to determine whether
there were marked differences in the level of neurogenesis occurring in the tissues of diabetic
and normal mice. The tissues obtained for staining and experimentation were donated by Dr.
Cheng’s lab as leftover frozen specimens from previous experiments. They used the procedure
below for perfusing the mice, removing the brain, and preserving the tissues, prior to storage in a
-80°C freezer for two to three years (IACUC 15-19).
Method for Perfusion, Removal, and Preservation of Mouse Tissues
1. Three-month old FVB (wild type normal) and OVE26 (diabetic) mice were injected with
a sub-lethal dose of sodium pentobarbital (i.p.,100ug/g) sufficient to induce deep
anesthesia. Suitable depth of anesthesia was determined by the absence of the hind-paw
pinch withdrawal reflex.
2. An incision was made bilaterally from the tip of the sternum to the axillary region of the
mouse, and the flap of skin was gently removed upwards to expose the ribcage.
3. The tip of the sternum was lifted using a small pair of forceps, and an incision was made
near the base of the sternum and continued along the base of the ribcage toward the spine
on both sides, stopping approximately 2 centimeters short of the spine.
4. The tip of the sternum was clamped with a small pair of hemostats, and the rib cage was
cut bilaterally approximately 1.5 cm from the midline towards the clavicle. The central
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part of the ribcage was then lifted and held out of the way by weight of the hemostat to
expose the heart and lungs.
5. 0.1 mL heparin solution was injected into the left ventricle, and the animal was left alone
for 1 minute to allow heparin to circulate. The thoracic cavity was kept moist with warm
PBS during this procedure.
6. While the heart was still beating, a 22-guage needle was inserted into the left ventricle
and stabilized in position using a hemostat. The inferior vena cava was then located and
cut, opening the circulatory system for drainage. Warm PBS was then introduced into the
circulation through the left ventricle using a peristaltic pump at a low flow rate in order to
flush blood from the circulatory system. Blood and PBS coursed through the circulatory
system, and exited through the cut inferior vena cava on the way back to the heart,
draining into a collecting basin beneath the mouse.
7. When fluid draining from the IVC turned clear, a switch was made to cold Zamboni’s
fixative (2% paraformaldehyde, 15% picric acid in PBS, pH 7.4). Perfusion with
Zamboni’s fixative continued until the feet, tail, and tissues around the nose and mouth
picked up a yellow tint from the Zamboni’s fixative, and the limbs/tail stiffened.
Perfusion at this point was discontinued.
8. Using a small pair of scissors, an incision was made at the bridge of the nose between the
eyes of the mouse.
9. Using a small pair of forceps, the front part of the skull was alternately peeled away or
broken starting at the incision between the orbits. The bottom prong of the forceps was
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gently worked into the space between the brain and skull as the skull was carefully
removed to expose the brain. Care was taken not to damage the brain tissue.
10. The occipital lobe was removed last, with great caution taken to avoid damaging the
cerebellum or brainstem.
11. The head of the mouse was flexed forward to allow insertion of the bottom prong of the
forceps into the spinal canal starting with the first cervical vertebra. The forceps were
used to expose the brainstem and spinal cord, vertebra by vertebra, down to the level of
the 2nd to 3rd thoracic vertebra.
12. The meninges covering the brain and spinal cord were identified, then gently peeled
away.
13. Using the forceps, remaining bits of skull and vertebrae were removed from around the
brain and spinal column. The forceps were used to feel for sharp edges of bone prior to
removal of the brain.
14. Using a dull scalpel, the brain was gently separated from the base of the skull by inserting
the scalpel underneath the brain, gently severing cranial nerves and vessels, slowly lifting
the brain, working from the olfactory bulbs back to the brain stem.
15. Once the brain and spinal cord were separated to approximately the 2nd or 3rd thoracic
vertebrae, the spinal cord was cut as low as possible and the brain removed.
16. The freshly excised brain was placed into cold Zamboni’s fixative and allowed to postfix
overnight.
17. After postfixing, the brain was transferred into a 30% sucrose solution for cryoprotection.
Initially, the brain would float near the surface of the sucrose solution.
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18. After the brain had sunk to near the bottom of the sucrose solution, it was removed and a
razor was used to cut away the cerebellum and brainstem. The cerebellum was then
separated from the brainstem and discarded.
19. The brainstem and cortical/midbrain tissues were then embedded in Tissue-Tek O.C.T.
Compound (Sakura Finetek, USA) and frozen at -80o C.
Nissl Staining
Trial 1
Three month-old FVB and OVE26 mice brains were used in this study, and the tissues
were transferred to a cryostat (HM 505N) and mounted on a plate using freezing medium at a
setting of -25°C. 12 μm coronal sections of the hippocampus and olfactory bulb were cut. Mice
classified with the letter “L” were normal, while mice classified with the letter “D” were
diabetic.
Table 1: Sections from Normal and Diabetic Mice
Mouse
Identification

Hippocampus
Slices

Olfactory
Slices

L18
L121
D101
D107
D110

Yes
Yes
Yes
Yes
Yes

Yes
Yes
Yes
Yes
No

Notes

Olfactory bulb was very dry and kept crumbling;
unsalvageable

Nissl staining using cresyl violet was used to visualize the morphology of the neurons
and perform cell counts on sections capturing the hippocampus and olfactory bulb. The staining
was performed as follows. Slides containing the sections were permitted to air dry for 15 - 30
minutes prior to immersion into a series of twelve solutions for staining: 95% ETOH for 15
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minutes, 70% ETOH for 1 minute, 50% ETOH for 1 minute, DH2O for 2 minutes, DH2O for 1
minute, Cresyl Violet stain for 15 minutes, DH2O for 1 minute, 50% ETOH for 1 minute, 50%
ETOH for 1 minute, 70% acid ETOH for 2 minutes, 95% ETOH for 2 minutes, 95% ETOH for a
few dips, and finally 100% ETOH for 1 minute.12
Trial 2
The protocol in trial 1 presented many challenges to data collection, in that the brain
tissues had inherent damage, and the procedure for dehydrating the tissues proved too extreme
and contributed to small perforations seen under the microscope, especially since the sections
were only 12 μm thick. Therefore the protocol was modified and optimized, and applied to newly
cut 30 μm slices. Instead of dipping the slides into a series of solutions, a pipette was used to
deliver the solutions to each slide gently, so that minimal disruption would occur to the tissues.
Each slide was treated with cresyl violet for eight minutes, and then rinsed with 1x PBS buffer
two to three times. Then each slide underwent three rounds of treatment with Histoclear for three
minutes each, rinsing with 50% EtOH twice in between. Finally the slide was rinsed in 1x PBS
buffer and allowed to air dry prior to being fitted with a coverslip using mounting media. The
slides were viewed at 200X magnification, and individual photos of each field of view were
taken and compiled into mosaics via the software ImageJ.13 The DG, CA1, CA2, and CA3
regions of the hippocampus were identified, and the neurons in five different 200 μm2 areas were
counted using Inkscape and averaged.
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Figure 1: Counting technique using 200 micrometer grids via Inkscape

Fluoro-Jade C
Fluoro-Jade C is a form of fluorescent histological staining used to highlight neurons in
the process of degeneration.14 Slides containing 12 μm thick hippocampal slices of OVE26 and
FVB mice were utilized. 1% NaOH in 80% ethanol was pipetted onto each slide for five minutes,
followed by 2 minutes of 70% alcohol, and then 2 minutes of diH2O. Then 0.06% potassium
permanganate was placed on the slides for 10 minutes, before the slides were rinsed with
distilled water for 2 minutes. 0.0001% Fluoro-Jade C in 0.1% acetic acid was then added to the
slide for 10 minutes, and the slide was incubated in the dark during this interval. Six consecutive
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1 minute washes in distilled water followed, and then the slides were allowed to air dry for 5
minutes. Lastly, the slides were cleaned with Histoclear for 5 minutes, allowed to dry, and then
cover-slipped for visualization at 488 nm on the confocal microscope.
Immunohistochemistry: Musashi-1
Musashi-1 is a mouse RNA-binding protein that is highly expressed in the stem cells of
the central nervous system.15 Because it is expressed highly in neuronal and glial precursor cells,
and then its presence virtually disappears once the cell has fully differentiated, it is a prime
marker for detecting neurogenesis in tissue samples.15 For the preparation of each solution, refer
to Appendix B.
First, sections of the hippocampus were selected and hydrated by pipetting 50% EtOH
onto the slides for 30 seconds. Then the tissues underwent six 1.5-minute washes in PBS buffer
while being agitated on a rotating shaker. The excess moisture was removed from the slides, and
then a Super Pap Pen was used to draw circles around each individual section so that when the
antibodies were added they would concentrate on the sections themselves, and not migrate to
unoccupied areas on the slide. 15 mL of blocking solution containing BSA and normal donkey
sera was added to the slides, and they were incubated on a rotating shaker at room temperature
for two hours. Then 1.5 mL of primary antibody (1 μg/mL) were incubated overnight for
approximately 16-18 hours at 4°C in a humidified chamber. This was followed by 6 five-minute
washes in PBS-T while on the rotating shaker at room temperature. The secondary antibody
(1:500) was then incubated for two hours at room temperature, and the slides were again rinsed
with 6 five-minute washes with PBS-T on the rotating shaker. The slides were viewed on a
confocal microscope at 543 nm for excitation and 625 nm for emission.
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RESULTS

CA1
DG

CA2

CA3

Figure 2: A) OVE26 Mouse Hippocampal Mosaic Slide 18A and B) DG at 40X
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CA1
CA2
DG
CA3

Figure 3: A) FVB Mouse Hippocampal Mosaic Slide 30 at 20X B) DG at 40X
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Figure 4: Diabetic DG depicting hyperchromatic neurons
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Figure 5: Normal DG depicting hyperchromatic neurons
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Number of Deeply Nissl-Stained Hyperchromatic
Hippocampal Neurons Detected in Diabetic and
Wild Type Mice
140

Number of Neurons

120
100
80
Diabetic

60

Wild Type
40
20
0
DG

CA1
CA2
Region of the Hippocampus

CA3

Figure 6: Number of Hippocampal Neurons in the Diabetic versus Normal Mouse

Images were taken with a light microscope at 200X magnification of OVE26 and FVB
brain sections, then merged in MosaicJ by overlapping landmarks in the photos (Figures 2 and
3). Neurons were counted in the DG, CA1, CA2, and CA3 regions using 200 μm fields of view
generated through Inkscape. Then an average was taken and the results were graphed, revealing
that in all four areas, diabetic mice led with the highest number of hyperchromatic neurons, and
the differences were statistically significant in the dentate gyrus and CA1 region (Figure 6). Then
a view of the dentate gyrus in each was procured at 400X, in order to determine whether there
were differences in the degree of staining, in other words whether diabetic neurons absorb more
cresyl violet than their normal counterparts (Figure 2B and 3B). The comparison revealed that
diabetic neurons were hyperchromatic and stained more darkly. The arrows in Figure 2 and
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Figure 4 depict hyperchromatic neurons in the diabetic brain, which were consistently more
highly stained in comparison to the background tissue than the neurons depicted in Figures 3 and
5 for the normal mouse.

Figure 7: Fluoro-Jade C Staining of diabetic dentate gyrus at 40X as a Mosaic
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A

B

Figure 8: Fluoro-Jade C stain of normal dentate gyrus at A) 40X as a mosaic and B) 1000X
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Figure 9: Fluoro-Jade C diabetic DG at higher magnification
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Figure 10: Fluoro-Jade C normal DG at higher magnification
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Figure 11: Trial 2 for Fluoro-Jade C diabetic DG as a 40x mosaic

Figure 12: Fluoro-Jade diabetic stained cell at 100X from box in Figure 11
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Figure 13: Trial 2 for Fluoro-Jade C normal DG as a 40x mosaic

Number of Degenerating Neurons

Number of Degenerating Neurons in the
Dentate Gyrus of Diabetic and NonDiabetic Mice in Fluoro-Jade Staining
120
100
80
60
40
20
0
Diabetic

Wild Type
Mouse Type

Figure 14: Number of degenerating neurons in DG using Fluoro-Jade
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The Fluoro-Jade C stains were viewed under a confocal microscope at 488 nm at 40X
magnification, with a focus on the dentate gyrus. Mosaics were made for both the diabetic and
normal mice, both depicting the presence of degenerate neurons via the presence of hotspots
consisting of fluorescent green pigment (Figures 7 and 8A). Examples of degenerate neurons in
both tissue types are labeled with orange arrows in Figures 9, 10, 11, and 13. When counts of the
mosaics were performed, the number of degenerate neurons in the diabetic dentate gyrus
exceeded that of the wild type (Figure 14). In addition to degenerating neurons, which are
normally more oblong and irregularly shaped, some of the glial cells in the tissue also appear to
be degenerating, and are characterized as very round green intensities (Figure 8B and 12).
The first trial of Fluoro-Jade staining produced a greenish border around the dentate
gyrus of the diabetic sections, and a more faint border around the normal dentate gyrus, labeled
with yellow arrows in Figures 9 and 10. At first, it was thought to be background staining due to
insufficient rinsing or too little tissue clearance with Histoclear. However a second trial in which
the number of rinses was doubled, and the time exposed to Hisoclear increased from 3 minutes to
five minutes showed less background staining, but the same green border around the dentate
gyrus (Figures 11 and 13). The diabetic sections consistently showed more pigment in this area
than the normal hippocampal sections, leading to the possibility that there is increased
neurodegeneration in the ependymal cells as well as the DG neurons of the diabetic mouse in
comparison to the normal.
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Figure 15: Mushashi-1 immunohistochemistry for wild type DG slide 37 at 20X
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A

B

Figure 16: Musashi-1 immunohistochemistry of diabetic DG at A) 20X and B) 40X
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Immunohistochemistry using Musashi-1 antibodies was used to detect for differences in
neurogenesis. Figure 15A shows a part of the dentate gyrus for the wild type mouse at 20X, 15B
is at 40X magnification, and C1-C3 are consecutive 0.5 um slices through the section in panel B.
Figure 16A is an image of the diabetic dentate gyrus with a close-up of one panel at 40X. Ideally
there should have been a higher number of fluorescent hot spots for the wild type mouse,
indicating decreased neurogenesis in the diabetic model. However, in both tissues there was a
high degree of non-specific binding making these results inconclusive. Even the pattern of
fluorescence that was present did not suggest that the antibody bound specifically, since
Musashi-1 should be found cytoplasmically, but the antibody instead outlined the neurons from
this trial. This is depicted by the green arrows in Figures 15 and 16, where the borders of neurons
are clearly seen but very few antibodies penetrate the interior in comparison to the rest of the
tissue. There may be a pattern in the binding, but it is difficult to interpret without a secondary
stain.
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DISCUSSION
Analysis of Results
Nissl staining is performed with basic dyes, such as the cresyl violet used in these
experiments, and binds to the negatively charged nucleic acids present in the nucleus of the cells,
as well as the endoplasmic reticulum.12, 16 Because the cells in brain tissue all contain these
components, the stain does not differentiate between glia and neurons, but the neurons retain
more of the stain because of their high rate of protein synthesis, and are also distinguishable by
the irregular shape of their dendritic spines.16 When these neurons sustain any type of damage
and begin to undergo degeneration, the stain increases in density and the cells are considered to
be “hyperchromatic.”17 The results of the Nissl stains performed in these experiments indicate a
greater number of hyperchromatic cells in the DG, CA1, CA2, and CA3 regions of the
hippocampus for diabetic mice in comparison to the wild type control. By extension this means
that the hippocampus of a diabetic mouse sustains greater levels of neurodegeneration than the
normal, and the expected clinical manifestation would be cognitive deficit based on evidence
from the literature.
To confirm that the hyperchromatic neurons observed were in fact degenerating, and not
merely histological artifacts, a second set of experiments was conducted using Fluoro-Jade C.
The precise mechanism of this stain is unknown, however, the present theory is that dying
neurons release strongly basic molecules that attract the acidic Fluoro-Jade to it.18 This basic
“degeneration molecule” is a byproduct of the process of neurodegeneration and is inaccessible
to Fluoro-Jade unless the cell membrane is disrupted, therefore making it a prime indicator for
neuronal cell death.18 The data collected using confocal microscopy and this staining technique
26

clearly demonstrated an increased level of neurodegeneration in the diabetic mouse model in
comparison to the wild type control. Moreover, there was also a larger number of fluorescent
glial and ependymal cells present in the diabetic brain sections, revealing that diabetes decreases
the presence of these cells in the dentate gyrus as well.
Musashi-1 was used to quantify the number of progenitor stem cells in the hippocampus
of the diabetic and normal mice, in order to determine whether diabetes disrupts neurogenesis in
the dentate gyrus. The target of the antibody, Musashi-1, is a protein that binds RNA and is
expressed predominantly in the progenitor cells, and undergoes down regulation once the cell has
fully differentiated.19 With regards to the Musashi-1 experiment, the results obtained were
inconclusive. Despite the fact that binding of the antibody did occur in both tissues, most of it
appeared to be non-specific, especially since the protein being sought out is cytosolic, whereas
the data obtained showed a great deal of membranous binding, as depicted by the way the
antibodies often outlined the neurons in the tissue as opposed to penetrating them. This is most
likely due to secondary antibody becoming trapped between the cells, rather than a true
antibody-antigen interaction.
In the future, we would like to perform a greater number of trials with Fluoro-Jade C to
add more weight to the conclusion we obtained, which is that diabetes does incur greater
neurodegeneration in the hippocampus. Moreover, the Musashi-1 immunohistochemistry
protocol needs to be optimized in order to reduce non-specific binding and increase the
penetration of the antibodies into the brain tissue. This could be accomplished by using 8 μm
slices instead of 12 μm sections, and by blocking the tissue with BSA overnight as opposed to
only blocking for two hours. The concentration of BSA was also determined to be only 2%,
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when typically a 10% blocking solution is utilized, so a change in this regard would greatly
reduce nonspecific binding. Another possible change to the protocol to make interpretation of the
data more efficient would be incorporating a double stain with β-tubulin III, which would
produce an inline of the neurons and would help us determine where these Musashi-1 antibodies
are binding.
Moreover, we would like to attempt this immunohistochemical procedure with sections
of the olfactory bulb, to determine whether neurogenesis is inhibited in this area in diabetic mice.
This would be of significant importance because there are many neurodegenerative diseases that
have been linked to reductions in the sense of smell.20 The remainder of this thesis is dedicated to
exploring the clinical manifestations of increased neurodegeneration and decreased neurogenesis
in the hippocampus, the potential mechanisms behind neuronal cell death and cognitive decline,
and how these findings may influence current and future treatments of diabetes mellitus.
Cognitive Impairment
Clinical Manifestations
As treatments for insulin resistance improve and as patients continue to live longer with
diabetes mellitus, the effects of this disease have shown to be clinically more widespread than
previously thought, with effects reaching as far as the skeletal system and the CNS.21 In type 2
diabetics especially, direct correlations were made between elevated A1c levels and poor
performance on tests evaluating neurocognition, showing an inverse relationship between
glycemic control and cognitive performance.21 With regards to type I diabetics, moderate
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declines in processes related to problem solving, mental and motor speed, learning, and memory
were noted as well.7
Multiple studies have been performed evaluating the cognitive performance of diabetics
by relating the scores they receive on various tests to their blood sugar levels. When comparing
type I diabetics with an HbA1C level of less than 7.4% to those with a level greater than 8.8%,
the general trend shown was that the greater the glycemic control, the better the person’s
performance in academic achievement, verbal IQ scores, psychomotor efficiency, and memory.8
A hyperglycemic state was also associated with loss of focus, decreased speed in information
processing, and a larger number of errors in mental subtraction.8
Hypoglycemia too has been thought to be involved in the clinical manifestations of
neurocognitive decline, especially with regards to recurrent hypoglycemia or severe
hypoglycemic episodes requiring third party assistance. When a diabetic patient was presently
hypoglycemic, their performance in terms of prospective, delayed, immediate visual, and
working memory was impaired, along with their visual-motor skills and visual-spatial skills.8
This occurred regardless of whether the patient was aware or unaware of their low blood sugar.8
It is the effects of recurrent hypoglycemia that interest researchers the most however, because its
long-term impact on patients' cognition in a euglycemic state is what produces mixed results.8
Currently, such persons have been observed to have lower IQ scores, verbal skills, memory, and
attention, although even those who had a history of severe episodes did not show greater
impairment than diabetics who did not have that history upon performance of an eighteen-year
follow-up.8 The risks of having a hypoglycemic blood sugar level are often increased the greater
the glycemic control, especially if the patient is undergoing intensive insulin management in
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order to minimize their risks for vascular disease.8 It would therefore be of significant concern if
hypoglycemia was a culprit of severe cognitive decline, and providers and patients had to
balance the benefits of maintaining blood sugar with the risks of cognitive dysfunction. However
the current evidence is not really supportive of this view, as a study done on children who had
frequent hypoglycemic episodes showed that they had higher verbal and memory scores, not to
mention academic achievement, than diabetic children with less glycemic control.8 This would
allow researchers to hazard the opinion that overall, the benefits of more stringent glycemic
control compensate for any neurocognitive damage instigated by hypoglycemia.8
Despite the decrease in cognitive capacities in hypo- and hyperglycemic states, patients
suffering from diabetes mellitus are still at a cognitive disadvantage even in euglycemia. If
compared to their respective controls, type I diabetics consistently score less in overall cognition,
speed of information processing, visual and sustained attention, visual perception, mental
flexibility, and crystallized intelligence.8 On average, those with type 2 DM exhibit decreased
working memory, immediate and delayed recall, verbal fluency, executive function (also
considered to be frontal lobe function), processing speed, attention, and verbal retention and
fluency.8 Whether as a result of hypoinsulinemia or a reduction in the body’s ability to respond
to insulin, the distributional pattern of glucose metabolism in diabetic patients as they work on
memory tests is altered, showing more widespread activity in brain regions adjacent to those
normally activated during such tasks.22 Although it has yet to be confirmed whether these
observations are the result of cerebral defects, diabetic patients also present with a lack of
balance, slower walking, and a greater potential for falling.8
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As patients with diabetes progress to having complications such as angiopathy, changes
in functionality manifest by way of decreases in the connectivity and synchronization of neural
networks between different parts of the brain.22 Functional MRI revealed that type I diabetic
patients with microangiopathy suffered a reduction in functional connectivity in five separate
neural networks.22 These include the secondary visual network, ventral attention network,
sensorimotor network, language-processing network, and the left frontoparietal network.22
However, researchers were startled to find that while type I diabetics without microangiopathy
suffered from a decrease in functional synchronization in three of these networks, they actually
had greater connectivity in the sensorimotor and secondary visual networks than even
nondiabetics.22 Moreover, this has also been observed in patients with other pathological states
of the brain such as cognitive impairment and multiple sclerosis.22 Because the acquisition of
microangiopathy is considered to be characteristic of a later stage of diabetes, researchers have
come to the conclusion that as diabetes begins to incur minor brain damage, the brain undergoes
“functional reorganization” in a compensatory effort to stem the tide of dysfunction, thereby
increasing the functionality of certain areas.22 However, as seen in other diseases such as
multiple sclerosis, synchronization in brain activity eventually declines in all five networks.22
Also from a functional perspective, the electrophysiological changes in diabetic patients
also correlate to the progression of the disease as response potentials to certain stimuli actually
reveal a decrease in nerve conduction velocity.8, 23 The P100 wave for example is a potential that
is visually evoked and thought to originate in the visual cortex.7 The longer the patient has had
diabetes and the higher their HbA1C level, the greater the latency of that potential.7 Flash
electroretinopathy confirms this based on the fact that even before any opthalmoscopic
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indications of retinopathy are present, there are reduced potentials sent out from the retina.8 The
nerve response to acoustic stimuli is abnormal as well, and the auditory-evoked potentials from
the brainstem in diabetic patients are characteristic of “acoustic pathway impairment.”8
Moreover, the event-related P300 wave associated with memory processes and used particularly
whenever a target stimulus must be identified from the midst of standard stimuli has been shown
to have greater latency, and could be related to defects in attention and short-term memory in
type 2 diabetics.7, 8 Though normally seen in typical aging, the decrease in conduction velocity of
the P300 wave is much more pronounced in diabetics, and central somatosensory-evoked
potentials are also delayed.7, 8 To assess electrical activity in the cerebrum, EEGs were also
performed on diabetics, and in patients with type 2 DM there was “slowing in the EEG
frequency band analysis over the central cortex and reduction of alpha activity over the parietal
area.”8 When compared to outcomes of neurocognitive tests, these results were correlated to
reduced visual retention and could only be accounted for by the presence of diabetes because
hyperglycemic nondiabetics did not express these findings.8 Furthermore, because diabetes often
manifests as accelerated aging, decreases in hippocampal synaptic plasticity have been observed
and implicated as being one of the major causes of the disadvantages that affect diabetics in
terms of both memory and learning.7 According to Saladin, synaptic plasticity describes the
ability of the brain to transmit potentials from one neuron to another to create new connections,
and the ease with which this transmission occurs down a familiar neural circuit is related to how
memories are retained and new tasks are learned, or synaptic potentiation.23 Afferent activity at a
high frequency induces what is called long-term potentiation, while long-term depression occurs
when there is a prolonged period in which a low-frequency stimulus is detected, thereby causing
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a reduction in the strength of the synapse.7 Aging, or accelerated aging in the case of diabetes,
results in an increase in the threshold needed to induce an LTP and a decreased threshold for an
LTD.7
One of the many concerns that has arisen for patients with diabetes is the increased
prevalence of both Alzheimer’s and vascular dementia in this subset of the population, even
when other cofactors and comorbidities are taken into account.21 In diabetics, the risk of
acquiring dementia is actually doubled in comparison to non-diabetics, and a theory currently
exists insinuating that Alzheimer’s and insulin resistance may have the same or at least a similar
pathogenesis.7 Secondary to these debilitating cognitive states in the later years, elderly diabetics
were also found to be twice as likely to suffer from depression, which also affects their ability to
perform daily abilities and function cognitively.8 Epidemiological studies have shown that 11.3%
were cognitively impaired, 14.2% had clinical depression, and 17.5% had “moderate to severe
deficits in activities of daily living.”8
So far the signs and symptoms of decline noted were observed in older diabetics from
mid-life on, which might suggest that age is a necessary component for seeing the detrimental
effects of DM on the brain. However these cognitive deficits can be seen as early as childhood
and become more obvious the earlier the onset of the disease. From the age of two, children
diagnosed with DM show less positive incremental changes in learning with regards to block
design, speed of processing, general intelligence and vocabulary.8 By the time six years have
transpired since the time of diagnosis, they begin to manifest with debilitations in long-term
memory, executive function, processing speed, attention, and IQ.8 In those diagnosed at less than
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four years of age, the impairment in processing speed, executive skills, and attention was
significantly greater than in those who acquired diabetes after the age of four.8
Gender also elicits a difference in cognitive effects, as a greater performance gap exists
between diabetic men and their controls in tests of strength grip, oscillation, and somatosensory
ability in comparison to the deficit observed between female diabetics and their respective
controls.8 In addition, worse glycemic control correlates to a verbal intelligence decline in boys
ages seven through sixteen, an effect that is absent in their female counterparts.8
Modifications in Macrostructure
Upon examination, the brains of diabetic patients have revealed that these clinical
manifestations of cognitive decline are linked to changes in the macrostructure of the brain, and
more specifically, atrophy. Moreover, the extent of the atrophy is linked to the age at which
onset of the disease occurred, the prevalence of hypoglycemic episodes in the patient’s life, as
well as whether he or she was known to suffer from chronic hyperglycemia.21 Because these
factors vary from patient to patient, it explains precisely why the epidemiological studies done
on diabetics have mixed results regarding the localization and extent of these structural changes
on the brain.7, 22
Young adults diagnosed with type I diabetes in childhood, for example, exhibit reduced
white matter volume and changes in its microstructure, as well as reduced gray matter density
associated with memory and language processing.21 Children with severe hypoglycemic episodes
too show decreases in posterior parietal white matter, and in the gray matter of the cuneus and
precuneus gyri.8 Voxel-based morphometric studies indicate that the location of GM density loss
varies based on diabetic conditions, as those suffering from chronic hyperglycemia show reduced
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density in areas responsible for attention, memory, and language, while those with a history of
multiple hypoglycemic episodes have less GM in the cerebellar posterior lobe.8 The reduction in
density in type I diabetics was found predominantly in the thalamus, temporal lobe, and frontal
lobe. Strangely, diabetic children with a history of severe hypoglycemia exhibit a higher GM
density in the right prefrontal cortex, an area thought to correlate to self-recognition.8, 24
Studies have also discovered localized atrophy in the amygdala and hippocampus,
regions that also show degeneracy in Alzheimer’s disease.8 In other cases, certain areas of the
brain in type I diabetics were associated with disorganization of typical white matter tracts that
showed more preservation the greater the long-term blood sugar control.22 White matter tract
aberrations were also associated with areas of greater myelin degeneration, and may be linked to
the declines in cognitive performance.22
If diabetes mellitus leads to the complication angiopathy, diffuse abnormalities can occur
in the brain in patients younger than the age of forty, characterized by degenerative
modifications that are so marked that a dual pathogenesis has been implicated.7 Researchers have
concluded that the cerebral atrophy characterized by “widened sulci and/or enlarged ventricles”
on MRI and CT must be due to the combined effects of diabetic abnormalities in neural tissue
and ischemia induced by the angiopathy.7 Magnetic resonance imaging has also revealed the
presence of white hyperintensities that may be linked to the autopsy finding of ischemic lesions.7
Strongly correlated to the aging process, leukariosis in the white matter and basal ganglia have
been a consistent presence in the brain tissue of both type I and type 2 diabetics.8, 25
From a volumetric standpoint, significant changes have been observed in diabetic patients
that would indicate quite clearly that the aging process is not only accelerated on a cognitive, but
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anatomical level as well. Magnetic resonance imaging revealed that diabetic patients have on
average 2.5 cm3 of abnormal tissue, consisting of 5% grey, 8% deep gray, and 81% white
matter.25 The longer the duration of DM and the higher the fasting plasma glucose level, the
lower the normal tissue volume and the larger the ischemic lesions.25 The lesions themselves are
believed to be the result of “nonnecrotic demylination” originating from insufficient blood flow,
and have been linked to balance, gait, and cognition.25 In the long-term, a difference of 10 years
in diabetic onset made a difference of 4.28 cm3 in total gray matter and could not be accounted
for by the normal aging process, which typically only results in a loss of 2.4 mL.25, 26 As a result,
the brain of a diabetic patient looks roughly two years older than that of a nondiabetic for every
ten years of disease duration.25
One of the more unexplained phenomena with regards to macrostructural changes in the
brain involves the effect of recurrent hypoglycemic episodes in children with diabetes.21
Contrary to the data collected on adults with type I diabetes, in whom hippocampal volumes
remained consistent despite chronic hypoglycemia, children who had an early onset of DM and
also had chronic hypoglycemia had increased hippocampal volumes.21 The theory at present is
that the brain in a state of development will respond to hypoglycemic conditions in a different
manner than an adult brain.21
Potential Mechanisms of Pathophysiology
The pathophysiology of diabetes mellitus continues to remain elusive, making it difficult
to target the causative agents of cognitive dysfunction and therefore deliver a treatment.8
However multiple theories have been proposed, and it is possible that a combination of these is
responsible for the accelerated brain aging found in diabetics.
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Because diabetes affects the cardiovascular system by changing the nature of blood
vessels and their ability to perfuse certain tissues, these modifications have been implicated in
the cerebrovascular changes responsible for cognitive deficits. In addition to intracranial vessel
atherosclerosis, which is partly responsible for the two to six-fold increase in the likelihood of
thrombolytic stroke in diabetic patients, other microvascular abnormalities exist such as
thickening of the basement membrane in capillaries.7, 8 The microvessels undergo endothelial
degeneration, the walls of larger vessels accumulate more collagen and become inflexible, and
there is an overall decrease in perivascular nerve density.7 Hyaline atherosclerosis occurs in the
smaller vessels (with diameters less than one nanometer), and involves replacement of the
smooth muscle with fibrous tissue that thickens the intima.7
Changes in the blood flow of the brain consequently contribute to cerebral insult. For
example cerebral blood flow levels in type 2 diabetics at rest and in response to hypercapnia are
both markedly lower than those in their respective controls, and it has been theorized that prior to
detectable structural changes in the brain, the pathology begins at the level of hemodynamics as
the cerebral microcirculation begins to undergo modification.22 Any type of aging, whether it be
normal or the accelerated form seen in diabetes, results in a decrease in the ability of the cerebral
blood vessels to autoregulate their response to perfusion pressure changes.7 Vasomotor tone
regulation is diminished, and could be linked to the decreased density of VIP and serotonincontaining nerves found in STZ-injected rats.7, 22 Decreases in vasodilation mediated by nitric
oxide and increased vasoconstriction in the arterioles, along with hypertrophy of the smooth
muscle found in precapillary vessels have also been observed.7, 22 Patients with diabetes also
seem to have reduced levels of C-peptide, which when normalized increased cognitive function
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in humans and decreased hippocampal apoptosis in the rat model.8 This is due to C-peptide’s
actions in the endothelium, which involve its binding to a G-protein coupled receptor and
beginning a cascade of events that not only trigger the expression of nitric oxide synthase
(involved in vasodilation), but activate several transcription factors involved in mechanisms that
are anti-oxidative and anti-inflammatory.8, 27 Diabetic patients also seem to have greater
stimulation of the thromboxane A2 receptor, which may be responsible for the decreased
capacity of cerebral vessels to dilate as well.8
As regions of the brain receive less blood, cell death occurs and the cell loss results in an
additional decline in cerebral blood volume because the metabolic demands of the brain have
been consequently altered.7 This phenomenon is observed in normal aging at a less drastic rate
than in diabetic patients, and is also accompanied by morphological changes in neurons and glia
as the state of chronic hypoperfusion continues.7 In rats, the hippocampal CA1 neurons, which
are especially susceptible to the effects of ischemia, display higher levels of astrocyte
components and a reduction in microtubule-associated protein 2 in the dendrites.7 Lower
microtubule-associated protein 2 is actually an indication of early ischemic damage, and because
astrocytes are responsible for replacing dead tissue via the process of sclerosis or scarring, an
increase in astrocyte levels is also an indicator of cerebral ischemia.7, 23 As a result of vascular
disease that has developed due to the progression of DM, these patients often exhibit structural
changes such as demyelination of the spinal cord and cranial nerves, pseudocalcinosis, nerve
fibrosis, and brain degeneration throughout.8
Many theories exist to explain how hyperglycemia may be causing the detrimental
structural and cognitive changes in both type I and type 2 diabetics. The first is that
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hyperglycemia increases the flux going through the polyol pathway, a biosynthetic progression
involving two enzymes that convert glucose into sorbitol and fructose.8, 28 Sorbitol has been
correlated to an increase in diabetic lesions in the CNS, so if more substrate is present there will
be greater conversion to sorbitol.28 This substance has also been located in the peripheral nerves
of STZ-treated rats.8 Upon treatment with an aldose reductase inhibitor, the levels of sorbitol
decreased drastically and normal cognitive function was restored.8 Another possibility is that
excess glucose is shunted to the hexoamine pathway for the production of cerebral chitin, a
molecule that accumulates in Alzheimer’s patients and may also be the cause of abnormal
cognition in diabetics.8
Hyperglycemia can also result in accelerated AGEing, which refers to advanced glycated
end-products that are a form of non-enzymatic protein glycation caused by the high
concentration of glucose in the blood.7 This is an irreversible reaction that occurs as a function of
time and the concentration of reduced sugars resulting in a linkage with the free amino groups of
proteins.7 AGEs are found in normal aging, but concentrations are considerably higher in those
with DM or Alzheimer’s, and their production has been linked to an increase in ROS in cells.7, 8
AGEing also causes modification of the endothelial basement membrane, contributing to
vascular dysfunction and the decreased ability of blood vessels to respond to nitric oxide for
vasodilation.7 Thus AGEing may contribute to ischemia in the brain, which in turn could lead to
neuronal cell death. These substances have also been linked to higher levels of oxidative stress in
the diabetic brain, as observed by increased levels of lipid peroxidation products.7, 8 The number
of oxidized, dysfunctional proteins in the neurons is increased because there are higher levels of
reactive oxygen species being produced as the result of glucose autoxidation.7 Moreover,
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enzymes like SOD and glutathione catalase which function as ROS scavengers are also
irreversibly glycated and consequently have reduced functionality as the body’s natural
antioxidants.5 Certain markers linked to these biochemical changes have been found to be upregulated in the hippocampus, such as nuclear factor κB transcription factors and the S-100
protein.8 The former is a proinflammatory gene marker that is activated in the presence of AGEs,
while the latter is indicative of brain injury and binds to receptors for AGEs.8
In concert, hyperglycemia and ischemia have proven to be a dangerous combination, and
the elevation of blood glucose has been correlated to less efficient clinical recovery from
cerebrovascular events.8 The underlying mechanism is thought to be glutamate accumulation,
which occurs during hyperglycemia as the excitatory neurotransmitter causes damage to the
neurons when ischemic conditions are present.8 Another theory is that hyperglycemia
exacerbates ischemic damage by providing more substrate for conversion into lactate; this lactate
then results in cellular acidosis which potentiates the brain injury.8
On the other side of the spectrum, hypoglycemia too has been implicated as a pathogenic
mechanism for the neurological damage seen in diabetes. Normally seen as a result of tight
glycemic control, the areas most sensitive to hypoglycemic damage are the hippocampus, basal
ganglia, and cortex according to autopsy reports.8 The effects seem to be isolated to neurons
exclusively, while sparing oligodendrocytes and astrocytes, and present as multifocal or
widespread necrosis of the cerebrum.8 The ganglion cells also exhibit chromatolysis.8 Although
once thought to be a passive process in which neurons simply died of starvation, in reality
hypoglycemia may actually induce a cascade of events that result in overactivation of the
excitatory NMDA receptor.8, 29 This overactivation is by the massive release of aspartate, which
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targets the dendrites causing calcium fluxes that in turn cause membrane dissolution and
necrosis.29, 30 This would therefore make cell death the result of endogenous excitotoxins, which
in turn would explain the seizures present in severe clinical cases of hypoglycemia.30 Unlike
ischemia, which normally affects the brainstem and cerebellum, these regions are spared in
hypoglycemia and instead necrosis is typically detected in the dentate gyrus of the
hippocampus.29 There is therefore therapeutic potential in an NMDA receptor antagonist that
would shield type I diabetic children from possible hypoglycemic damage.8
Because intracellular concentrations of Ca2+, as well as the signal transduction cascades
induced by them, play a role in the pathway leading to neuronal cell death in the normal aging
process, an imbalance in Ca2+ is a possible mechanism for the cellular changes observed in the
CNS of diabetic patients.7 According to the literature, a drastic change in the calcium
concentration over a short duration produces the same amount of damage as an incremental
damage over a long period of time, and disruptions in calcium homeostasis are linked tightly to
ischemia, cell death, and the production of reactive oxygen species.7 Although there are few
details on precisely how this imbalance occurs, it does seem to influence the changes in LTD and
LTP observed in diabetic patients.7
Moreover these changes in cognition may be accounted for by decreases in hippocampal
synaptic plasticity, as well as fluctuations in neurotransmitter levels or their respective receptors.
According to studies done on STZ-injected rats, the deficit in plasticity is mainly postsynaptic
and the induction of diabetes in these rats was quickly followed by increased sensitivity to
adenosine, an inhibitory neuromodulator.7 Believed to be caused by reduced nucleoside uptake,
it is thought that increased levels of adenosine play a role in long-term potentiation deficits, since
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LTP is modulated by adenosine.7 Synaptic transmission is dependent upon effective binding of
glutamate to NMDA and AMPA receptors, so it is interesting to note that in diabetic rodent
models, the density of NMDA receptors found in the hippocampus is significantly reduced.7, 8
Moreover, glutamate has a decreased affinity for AMPA receptors because the GluR1 subunit
has reduced expression.7 The result is an impairment of LTP, which is a cause of learning
deficits and can be ameliorated by insulin treatment.8 Other observations include decreases in
ACh levels, which led to amnesia and hyperactivity in STZ rats in relation to the control,
decreased dopamine activity, and lower serotonin degradation.8 The conclusion arrived at by
researchers is that fluctuating blood sugar levels seen in patients with poor glycemic control have
a detrimental effect on the function of multiple neurotransmitters in the brain.8
Perhaps the biggest lead with regards to why diabetes mellitus increases and exacerbates
cognitive decline in patients comes from the very cause of diabetes mellitus itself: insulin
resistance. Although the effects of insulin on metabolism in peripheral tissues is relatively well
understood, little is known about the effects of insulin on brain metabolism as the brain was
originally thought to be insulin independent in this regard.8, 31 Despite the fact that insulin
receptors have been found on the endothelium of the blood brain barrier, hypothalamus, cortex,
cerebellum, amygdala, olfactory bulb, and hippocampus, and studies have shown that insulin
does indeed penetrate the CSF and spread globally throughout the CNS, data from PET scans
indicate that increasing insulin levels does not increase the uptake of glucose in the brain.8, 31 But
if this is the case and insulin resistance plays no role in the pathogenesis of DM, why is it that
those with Alzheimer’s disease have greater insulin resistance and are at a higher risk of
developing DM, and why is that those with DM are 1.2 to 1.7 times more likely to acquire
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Alzheimer’s disease?8 The studies performed on these correlations actually suggest the same or a
similar pathogenesis between the development of these two diseases, and the root lies in insulin
resistance.8 Those with Alzheimer’s seem to actually secrete more insulin in response to a
glycemic load, and this “desensitization of neuronal insulin receptors” is what is believed to
contribute to the development of sporadic Alzheimer’s disease in diabetics.8
Other observations have been noted to exist in both diabetics and those with Alzheimer’s
that may lead scientists and clinicians closer to the cause of cognitive impairment in these
patients. First is the increased prevalence of inflammatory markers such as IL-6, C-reactive
protein, and α-1-antichymotrypsin in any patient with insulin resistance.8 The second observation
was disturbance of the hypothalamic-pituitary adrenal axis leading to excess levels of cortisol,
which correlated to poorer memory performance and damaging structural changes in the
hippocampus.8 The last observation was that DM patients had increased formation of senile
plaques commonly found in Alzheimer’s patients, which are the result of cleavage of amyloid
precursor protein in neurons into β-amyloid.8 Insulin-degrading enzyme is typically responsible
for the breakdown of APP and β-amyloid, and is up-regulated by the presence of insulin.8
However in an insulin resistant environment, higher glucose levels result in AGEing, and the
enzyme instead binds to RAGEs (Receptor for Advanced Glycated End Products); the plaques
are allowed to accumulate, thus bringing about glial and neuronal dysfunction.8
Cardiovascular Neuropathy and the CNS
According to the Toronto Consensus Panel on Diabetic Neuropathy, sudden cardiac death
is two to four times more likely in type 2 diabetics than any other subset of the population.32
What is even more surprising is that this alarming statistic is not the product of accumulated
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comorbidities that usually present with diabetes, but rather SCD is more prevalent because of
cardiovascular autonomic neuropathy, a term assigned to “the impairment of cardiovascular
autonomic control in the setting of diabetes after the exclusion of other causes.”32 Present in
about 20% of the diabetic population, its prevalence can increase, depending on the duration of
diabetes and age, to 65%. 32
CAN is characterized by damage to the autonomic nerves that provide innervation to the
blood vessels and heart.33 Because the ANS is primarily responsible for regulating heart rate
variability and cardiac performance, damage to these nerves manifests as silent myocardial
infarction, intraoperative cardiovascular liability, exercise intolerance, orthostatic hypotension,
and resting tachycardia.33, 34 All of these classic signs are linked to neuropathy that begins
peripherally and works its way proximally.34 Moreover, because neuropathy affects longer
nerves first, the vagus nerve is affected almost immediately and parasympathetic activity is
severely down-regulated, as the tenth cranial nerve is normally responsible for 75% of
parasympathetic function.34
Underlying all these clinical manifestations is a distinct inability of the body to interpret
sensory stimuli and respond appropriately. With regards to exercise intolerance, for example,
autonomic dysfunction minimizes the normal rise in blood pressure and heart rate that would
normally occur, thereby reducing cardiac output and the person’s ability to supply their more
metabolically active tissues with oxygen.33 The tachycardia observed is from impairment of the
vagus nerve, which results in sympathetic overactivation characterized by abnormal
norepinephrine metabolism and signaling.32, 34 QTi prolongation is also present, which is
quantified as the delay in ventricular repolarization, and could be the reason why type I diabetics
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suffer from arrhythmias and are more prone to the ‘dead in bed’ syndrome.32 Such cardiac
rhythm disturbances are thought to be the result of electrolytic myocardial changes, as well as
imbalances in sympathetic innervation.32 Orthostatic hypotension is thought to be the result of a
reduction in the norepinephrine response that is proper for a relative drop in blood pressure, and
would indicate a defect in the “centrally mediated” baroreflex.33 Reduction in the ventilator drive
induced by hypoxia has also been observed in diabetic patients with CAN.33 Even in sleep, blood
pressure variations based on circadian rhythms are improperly regulated, resulting in nocturnal
hypertension.32, 34
Although neuropathy is often a complication of diabetes mellitus and plays a role in
much of the cardiovascular dysfunction observed in the diabetic population, the decreased
effectiveness of certain cardiac and respiratory reflexes would suggest that diabetes might have a
detrimental effect on heart rate variability via central influences as well. A study conducted on
STZ-injected rats revealed that they had decreased sensitivity to neuropeptide Y, which led them
to conclude that chronic diabetes results in a decrease in the sensitivity of NTS neurons to certain
neurotransmitters, and as a result sensory stimuli.35 In addition, diabetes may also influence the
neurotransmitter metabolism.2 One circulating hypothesis is that cardiovascular autonomic
neuropathy is instigated by the “dysregulation of neuropeptides, such as calcitonin gene-related
peptide (CGRP) and vasoactive intestinal peptide (VIP)” and is characterized by prolongation of
the interval of ventricular depolarization and repolarization.36 The cause seems to be irregular
plasma levels of CGRP, ANP, VIP, NPY, and SP, whose vasomodulatory effects are what
maintain cardiovascular homeostasis.36 Thus there exists a potential mechanism stemming from
the central nervous system by which diabetes mellitus might influence cardiovascular function.
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Effects of Diabetes Mellitus on Neurogenesis
Neurogenesis is defined as the process by which progenitor cells of the brain differentiate
and becoming integrated on a functional level in the adult brain.37 After development of the
mammalian brain in utero, this plasticity becomes limited to a few defined regions, such as the
dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles, while the
rest of the cerebral cortex is limited to neurogenic-to-astrogenic transformations.38, 39 In the
subgranular zone of the DG, for example, progenitor cells proliferate and then travel to the
granular cell layer.38 The stimulus for a plastic event usually stems from the environment, or a
multiplicity of factors involving stress, pathological situations, aging, hormones,
neurotransmitters, growth factors, neurodegeneration, or inflammation.37 Neural progenitor
proliferation is consequently induced by a large multitude of transcription factors that are able to
“sense” these changes and appropriate the proper physiological response, and often the
production of these new hippocampal neurons is associated with memory formation and
learning.37, 38, 39 With regards to differentiation, it is surprising to note that most newly generated
neurons actually do not survive even in a normal physiological state, making the integration of
those that do survive of even greater importance.37 Moreover, because the addition of new
neurons in response to external and internal stimuli is purposed to optimize the communication
between the CA3 pyramidal subfield and the dentate gyrus, any changes to the process of
neurogenesis itself could influence and potentially interfere with the functions of this brain
region.38
In diabetes, the state of the brain is not favorable towards the normal process of
neurogenesis, and according to the literature, hippocampal alterations occur long before diabetes
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clinically manifests, as early as the pre-diabetic state.37 In NOD mice, for example, there was a
50% decrease in the rate of cell survival in the dentate gyrus, an overall low level of
proliferation, and hippocampal astrogliosis was also observed.37, 38 These pathological signs are
normally descriptors of aging and stress-induced depression, but unfortunately are not the only
features of premature decline in diabetics.37, 38 In addition to early astrogliosis and low DG
neuron count, increased levels of microglia indicative of ongoing inflammation are often present,
in addition to greater expression of immune response genes, cytokines, and cytokine receptors.37
This inflammation is detrimental for neurogenesis in the hippocampus and has also been
implicated in the progression of Alzheimer’s disease and depression.37
Alterations in the structure of the diabetic hippocampus have also been correlated to the
presence of the neuromarker apolipoprotein-E, which is normally a sign of neuronal
dysfunction.40 Typically, this protein enters neurons when the cell is undergoing repair following
some form of insult or injury, and is expressed by ependymal cells, astrocytes, and
oligodendrocytes.40 Apo-E is thought to facilitate the removal of cellular debris because when
the gene encoding it is mutated, the products of degeneration remain in the hippocampal cells.40
Moreover, the worse the hippocampal injury, the greater the intensity of Apo-E expression in
neurons that are degenerating, and most especially in the pyramidal neurons of CA1 and CA3.40
Considered to have a neurotrophic role involved in learning and neuroplasticity, Apo-E
expression has been linked to an attempt by the body to counter the progression of
neurodegeneration.40 In addition, there is abnormal expression of the genes coding for proteins
that would normally induce neuronal activation, such as Jun+ in the DG, CA1, and CA3
regions.40
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One of the main reasons why diabetes is detrimental to the brain state, and more
specifically hippocampal neurogenesis, is because diabetes is a metabolic stress. Although stress
would normally induce neuroplasticity in order to invoke adaptation to the stimuli, prolonged
exposure actually instead produces an interminable burden resulting in allostatic overload.41
Consequently, there is an increase in the expression of hypothalamic hormones, which in turn
lead to overactivation of the hypothalamo-pituitary-adrenal axis (increasing cortisol levels) and
an elevation in the sensitivity of the brain to stress.38, 40 Moreover because the hippocampus is
rich in glucocorticoid receptors, and because glucocorticoids regulate hippocampal neurogenesis
negatively, the result is a decreased number of new neurons in the dentate gyrus.37, 38 Other
effects of this metabolic stressor include increased expression of apoptosis markers in the
hippocampus, as well as reductions in the expression of synaptic proteins and dendritic spines.41
Because dendrites actually comprise 95% of the total neuronal volume, this would account for
why diabetics have reduced hippocampal volumes.41
Current studies have made an association not only between diabetes and
neurodegenerative diseases such as Alzheimer’s, but depression as well.37 Epidemiological
studies reveal that depression occurs at a rate of 12% in the type I diabetic population versus
3.2% in the non-diabetic population, and 19.1% in type II diabetics versus the general
populace.41 This reveals an interesting relationship between the comorbidities, which is
reciprocal in the sense that diabetes increases the chance of suffering from depression and
depression increases the likelihood of diabetes.41 Although poor self-care and lack of medical
adherence may be at the root of this issue, insulin resistance in the brain is a more likely culprit
as the link between the acquisition of depression and diabetes.41 As a result of hyperinsulinemia,
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there are alterations in the levels of dopamine and serotonin in the CNS, as well as
neurotrophins.41 Moreover, studies performed on animal models of depression and diabetes
showed defective and reduced neurogenesis in the dentate gyrus, with decreases in hippocampal
cell proliferation as large as 56% in comparison to the 27% decrease in diabetic rodents without
depression.37, 41 Neuronal differentiation also suffered a decline in depressed diabetic rats by a
difference of 17%, and cell survival was diminished by 44% in comparison to the diabetic
model, which only suffered a 15% decrease in survival.41 Researchers therefore made the claim
that depression occurs as a result of a decline in hippocampal neurogenesis below a certain
threshold.41 Because diabetes interferes with neurogenesis in the brain, a subset of the diabetic
population will reach and pass that threshold, resulting in depressive behavior.41 In support of
this conclusion, treatment with antidepressant medications actually restores neurogenesis in the
hippocampus to some degree.37
A newer area of study involving the effects of cognition and behavior, and to which the
effects of diabetes would be interesting to explore, is related to another area of neurogenesis, the
olfactory bulb. Although more crucial to the behavior of animals such as mice, in the mammalian
brain in general, progenitor neuronal cells are known to travel from the subventricular zone to
the olfactory bulb via the rostral migratory stream.20 Once there, these stem cells become
inhibitory interneurons through the process of differentiation.20 In a study involving a mutated
erk5 gene, a sequence which codes for the signaling protein EPK5 that helps to regulate
neurogenesis in the SVZ-RMS-OB axis, researchers observed that the mice had reduced shortterm memory for certain odors, insensitivity with regards to odor detection, and deficits in
olfactory-dependent behaviors.20 This finding has great significance in that many
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neurodegenerative diseases, injuries, and even ordinary aging are linked to impairment in
olfaction.20 It would therefore be considerable if a strategy was developed by which the decline
in olfactory function could be halted and potentially mitigated in order to restore olfactory-linked
functions in behavior and memory.20
Implications for Current and Future Treatments
Although current treatments have managed to extend the length and quality of the lives of
diabetic patients by reducing the incidence of complications, it has not been sufficient to wholly
prevent its toll on their peripheral nerves, hearts, eyes, vasculature, and kidneys.21 Some studies
have even suggested that current treatments may be the very cause of cognitive dysfunction and
the increased prevalence of dementia in older diabetic patients.7
The first concern is that tighter glycemic control increases the prevalence and severity of
hypoglycemic episodes, which have been previously implicated as the cause of decreased
cognitive ability in diabetics. Occurring as often as 30 times per year, these events are
characterized by malaise, hunger, anxiety, diaphoresis, and tremors, and the more often they
occur the more likely the patient is to acquire hypoglycemia unawareness.42 Blunting of the
counterregulatory response to hypoglycemia can in turn lead to neuroglycopenia characterized
by confusion and seizures, and persistent hypoglycemia is associated with a torrent of
sympathetic activity via the release of catecholamines.42 The resulting hemodynamic changes are
thought to precipitate events of cerebral ischemia, and it is that reduced blood flow that could be
the very mechanism for neurodegeneration on a regional and global level in the diabetic brain.42
There are, however, two sides to this concept. Though diabetic patients from epidemiological
studies in an ambulatory setting did have a higher risk of cerebrovascular events if they had a
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prior history of hypoglycemia, those that chose to participate in an intensive insulin therapy
group and were consequently more prone to hypoglycemia did not.42 Therefore, it may be
concluded that the cardioprotective benefits of these more intensive therapies outweigh the
effects of hypoglycemia.32, 42
Other studies have posed that insulin itself, and not hypoglycemia, is the culprit of “agerelated memory decline and diabetic encephalopathy.”7 Though once thought incapable of
crossing the blood brain barrier (with the brain itself considered an insulin-independent organ)
this hormone has been found in abundance in the hypothalamus and olfactory bulb, and its
receptors have been found in the hippocampus and limbic system as well.7 Researchers postulate
that insulin enables a gradual amassment of oxidized proteins by competitively inhibiting the
role of insulin-degrading enzyme in protein turnover.7 Moreover, insulin actually inactivates a
family of transcription factors that would normally allow the expression of genes responsible for
defending against oxidative stress.7 This has been correlated to the observation that of the
population suffering from type 2 diabetes, those undergoing insulin therapy have the greatest risk
of developing dementia.7
Furthermore, although most studies indicate that insulin is beneficial in the CNS because
it increases the activity of insulin-degrading enzyme, which is responsible for the breakdown of
senile amyloid plaques, others have suggested that insulin decreases intracellular levels of βamyloid by facilitating its secretion.8 This would raise levels of extracellular β-amyloid, which is
allegedly responsible for memory loss and the development of Alzheimer’s disease.8 Such
conflicting results foster a greater sense of urgency for research in this field, so that the causative
agents of cognitive decline do not turn out to be rooted in present-day treatments.
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According to the literature, some of the findings related to macrostructural brain changes
and their related pathological mechanisms suggest possible avenues in and of themselves for
ameliorating the progression and severity of cognitive decline. The study that discovered that
brain glucose metabolism in type 2 diabetics is more widespread regionally than in their
nondiabetic counterparts, for example, found that increasing metabolism in the normally
activated regions resulted in better performance on memory tests.22 Moreover, a reduction in the
modifiable vascular risk factors thought to be associated with the development of Alzheimer’s
and VaD would decrease the likelihood of such pathological states manifesting in older diabetics,
especially if treated prior to the development of clinically significant cerebrovascular disease.22
These forms of secondary prevention would also reduce the risk of strokes and cardiovascular
disease, and improve recovery rates in diabetics, a subset of the population in which risks are
already higher than normal and rehabilitation outcomes less than satisfactory.8, 22
Such an emphasis has been placed on increasing the foundational understanding of
diabetes mellitus and its neurophysiologic and structural effects on the brain because with
regards to quality of life and functional ability in the elderly, cognition plays an important role.22
With its decline comes an actual decreased response to treatments for various medical
conditions; therefore better comprehension of the progression, pathophysiology, and risk factors
that accentuate these cognitive defects will allow healthcare providers and patients to take
advantage of earlier windows of opportunity where medical interventions will prove most
effective.22
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APPENDIX A: ABREVIATIONS
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
Apo-E: Apolipoprotein E
CA1: Cornu Ammonis area 1
CA2: Cornu Ammonis area 2
CA3: Cornu Ammonis area 3
CAN: Cardiovascular Autonomic Neuropathy
CBF: Cerebral Blood Flow
CNS: Central Nervous System
CSF: Cerebrospinal Fluid
CT: Computed Tomography
DG: Dentate Gyrus
DM: Diabetes Mellitus
EEG: Electroencephalogram
FVB: Friend Virus B (Non-diabetic transgenic mouse model)
GM: Gray matter
HbA1c: Glycated hemoglobin
LTD: Long Term Depression
LTP: Long Term Potentiation
MI: Myocardial Infarction
MRI: Magnetic Resonance Imaging
NMDA: N-methyl-D-aspartate
OB: Olfactory Bulb
OVE26: Transgenic type I diabetic mouse model
PET: Positron Emission Tomography
RAGE: Receptor for advanced glycated end products
RMS: Rostral Migratory Stream
ROS: Reactive Oxygen Species
SCD: Sudden Cardiac Death
SOD: Superoxide Dismutase
STZ: Streptozotocin
SVZ: Subventricular Zone
WM: White matter
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APPENDIX B: SOLUTIONS FOR IMMUNOHISTOCHEMISTRY
BSA Stock, 0.04 g/mL (50 mL)
 2 g BSA (Bovine Serum Albumin) powder
 Bring to 50 mL with PBS in 50 mL conical tube
 Mix well by vortexing
Triton X 100 (TX-100) Stock (50 μL/mL, 50 mL)
 2.5 mL TX-100
 Bring to 50 mL with PBS in 50 mL conical
 Mix well by vortexing
Sodium Azide (NaNH3) Stock, 8 mg/mL (10 mL)
 Bring 80 mg (0.08g) sodium azide to 10 mL PBS in 15 mL conical tube.
 Mix well by vortexing
10X PBST, 30 ul/mL TX-100 (50 mL)
 1.5 mL TX-100 to 50 mL PBS
 Mix completely by vortexing
PBS-T, 3 uL/mL TX-100 (50 mL)
 5 mL 10 PBS-T
 Bring to 50 mL in PBS
Blocking Solution (15 mL)
 3.750 mL PBS Buffer
 7.500 mL BSA Stock
 0.750 mL Normal Donkey Sera
 1.500 mL NaNH3 Stock.
Primary Antibody, 1ug/mL (1.5 mL)
 0.480 mL PBS Buffer
 0.750 mL BSA Stock
 0.090 mL TX-100 Stock
 0.030 mL Normal Donkey Sera
 0.150 mL NaNH3 Stock
 0.015 mL Primary Antibody [Abcam Rabbit Polyclonal anti-musashi1 antibody (ab21628,
Lot# GR 72252-1), 100ug/mL]
Secondary Antibody (1:500)
 1.5 mL PBS-T
 3 μL Secondary Antibody [Alexafluor Donkey Anti-Rabbit (a21207, Lot# 421207), 2 μg/mL]
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